SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
SeaStar Medical's Chief Medical Officer Kevin Chung will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children's Hospital in Houston on October 6-8. His presentation will highlight QUELIMMUNE, the company's FDA-approved therapy for critically ill pediatric patients with AKI and sepsis, as a case study in medical device innovation. The release recaps previously published data — a 77% survival rate in the registration study and early SAVE Registry results showing 76% survival at Day 28/60 — but contains no new clinical or financial disclosures.
Key figures
- Registry patients
- 21
- Trial survival rate
- 77% (registration study, Kidney Medicine)
- Registry survival day90
- 71%
- Neutralize aki enrollment
- 339
- Registry survival day28 day60
- 76%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.